US mRNA specialist Moderna (Nasdaq: MRNA) has announced positive interim data from a Phase II/III study of the company’s vaccine against COVID-19, in children aged six to under 12 years of age.
This interim analysis showed a robust neutralizing antibody response and favorable safety profile after two doses of mRNA-1273, a vaccine manufactured under the brand name Spikevax.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze